Supplementary figures - Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma
figureposted on 2022-04-29, 08:29 authored by Ninad Shah, Ali Mojebi, Dieter Ayers, Shannon Cope, Sujith Dhanasiri, Faith E. Davies, Parameswaran Hari, Payal Patel, Kristen Hege, Devender Dhanda
Supplemental figure 1. HRs of OS for ide-cel versus conventional care based on the triple- or quad-refractory population from MAMMOTH.
Supplemental figure 2. HRs of OS for ide-cel versus conventional care based on the penta-refactory population from MAMMOTH.